ETRADE Capital Management LLC Increases Position in IDEXX Laboratories, Inc. (IDXX)
ETRADE Capital Management LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,788 shares of the company’s stock after acquiring an additional 230 shares during the period. ETRADE Capital Management LLC’s holdings in IDEXX Laboratories were worth $611,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. BlackRock Inc. grew its stake in IDEXX Laboratories by 1,967.1% during the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock valued at $993,680,000 after acquiring an additional 6,116,102 shares in the last quarter. Vanguard Group Inc. grew its stake in IDEXX Laboratories by 24.3% during the 1st quarter. Vanguard Group Inc. now owns 8,910,555 shares of the company’s stock valued at $1,377,660,000 after acquiring an additional 1,740,446 shares in the last quarter. State Street Corp grew its stake in IDEXX Laboratories by 38.6% during the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock valued at $604,793,000 after acquiring an additional 1,089,880 shares in the last quarter. Old Mutual Global Investors UK Ltd. purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at about $83,723,000. Finally, Renaissance Technologies LLC grew its stake in IDEXX Laboratories by 59.1% during the 1st quarter. Renaissance Technologies LLC now owns 975,600 shares of the company’s stock valued at $150,838,000 after acquiring an additional 362,400 shares in the last quarter. 87.64% of the stock is owned by institutional investors.
In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 13,000 shares of IDEXX Laboratories stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total transaction of $1,960,270.00. Following the completion of the transaction, the chairman now owns 1,044,034 shares in the company, valued at $157,429,886.86. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rebecca M. Henderson sold 5,156 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $153.29, for a total transaction of $790,363.24. Following the transaction, the director now owns 17,274 shares of the company’s stock, valued at approximately $2,647,931.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is currently owned by company insiders.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at 156.45 on Thursday. The stock has a 50 day moving average of $154.86 and a 200 day moving average of $159.27. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01. The stock has a market cap of $13.65 billion, a PE ratio of 53.82 and a beta of 0.49.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.10. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.74 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.
Several analysts recently issued reports on IDXX shares. Aegis started coverage on shares of IDEXX Laboratories in a research note on Wednesday, May 31st. They set a “sell” rating and a $118.00 price objective for the company. They noted that the move was a valuation call. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, June 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, June 13th. BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $174.00.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.